Eli Lilly TRAILBLAZER-ALZ 5 I5T-MC-AACO (Phase 3)
About the trial
WA only
Donanemab is a human monoclonal antibody targeting amyloid beta that is present only in the deposited amyloid plaque in the brain. In previous clinical research, Donanemab has demonstrated the ability to reduce brain amyloid plaque, and it is expected to slow the progression of Alzheimer’s disease.
Who can be involved:
• Male or female, aged 60 – 85 years inclusive
• Must be diagnosed with MCI or mild Alzheimer’s disease
• Has an identified, reliable, study partner
• If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening
What is involved:
• Visits: Every month for 76 weeks
• 93 weeks trial duration total
• IV infusion once a month
• Must be able to tolerate MRI and PET scans
• Willing to travel to Melbourne (all expenses paid) every 6 months for PET scans
• 50% chance of receiving placebo
Additional info:
For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimersresearch.org.au
* Please note that participants in this study may have a chance of being placed on a placebo medication
